Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Is Betting On Byetta LAR

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Lechleiter is “confident” that clinical data expected this quarter on Lilly’s follow-on Byetta LAR will overcome FDA concerns over Byetta.

You may also be interested in...



Liraglutide Up For Approval In U.S. And Europe

Novo Nordisk’s type 2 diabetes drug could face hurdles once longer-acting GLP-1s hit the market.

Liraglutide Up For Approval In U.S. And Europe

Novo Nordisk’s type 2 diabetes drug could face hurdles once longer-acting GLP-1s hit the market.

Amylin CEO: Firm Can Do Better With Byetta

Diabetes drug so far has failed to catch on with primary-care docs.

Related Content

Topics

UsernamePublicRestriction

Register

PS065214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel